Your ELTP DD Root Source

10 GREAT DD Links for You to Absorb.  For investors new, long and undecided - allow these to help pave the way. 

1) http://www.wsw.com/webcast/rrshq23/register.aspx?conf=rrshq23&page=eltp&url=http%3A//www.wsw.com/webcast/rrshq23/eltp/

2) http://seekingalpha.com/article/1518902-elite-pharmaceuticals-ceo-discusses-f4q-2013-results-earnings-call-transcript

3) http://seekingalpha.com/article/1688112-elite-pharmaceuticals-call-it-a-comeback-story

4) http://seekingalpha.com/user/4199131/instablog

5) http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92544794

6) http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92373368

7) http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92212898

8) http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92170858

9) http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92034478

10) http://investorshub.advfn.com/boards/read_msg.aspx?message_id=87338918

Article - Elite Pharmaceuticals: Call It A Comeback Story

From a ELTP "long" investor.... In my previous article published on May 28th titled Actavis: Abuse-Deterrent Opioid Connections, I noted connections and relationships to watch for between Actavis (ACT) and several companies. As it turns out, several of these companies have played a role in the re-emergence of the relatively unknown Elite Pharmaceuticals (ELTP.OB). This article will examine these recent events and evaluate the opportunity this presents to investors. In my opinion, this is an incredible comeback story that will not go unnoticed much longer. About seven years ago, Elite Pharmaceuticals traded on the AMEX, was popular among investment firms, and had a bright future with controlled release and abuse resistant opioid technologies. However, mistakes by management, coupled with the down turn in the economy left the company short of being able to attain their goals and on the verge of bankruptcy. An interesting read is this 2006 interview in the Wall street Journal with the former CEO Bernard Berk. Elite was an innovator but ran out of time and money when the market crashed shortly thereafter. The technology was there but the financial sustainability was not. A stock that used to trade for dollars now trades for eight cents. But that is starting to change. What has happened since May 28th? In June they announced sales of their existing drugs resulted in a record quarter. In August they announced senior management from Actavis has taken over key roles at Elite. In addition in August they announced numerous FDA approved drugs have been added to Elite's growing pipeline. In their most recent earnings conference call Elite announced they were on the verge of getting their abuse deterrent products into the final stages needed to garner FDA approval. During the Rodman and Renshaw Conference, CEO Nasrat Hakim noted that they have been approached by several companies regarding Elite's technology including meetings with a CEO the day before and the Chairman of a major pharmaceutical company two weeks prior. Elite previously cited in their filings "doubt as to our ability to meet our business objectives and to continue as a going concern." Their most recent 10q removes that language. Read the rest of the article here: Seeking Alpha ELTP Article

PR: Elite Pharmaceuticals Announces Manufacturing and License Agreement for Twelve Generic Products

Read This PR! Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today the signing of a Manufacturing and License Agreement ("Agreement") with Epic Pharma, LLC ("Epic"). Pursuant to the Agreement, Epic will have the right to manufacture, market and sell in the United States and Puerto Rico twelve generic products owned by Elite. Of the twelve products, Epic will have the exclusive right to market six products and the non-exclusive right to market six additional products. Epic is also responsible for all regulatory and pharmacovigilance matters related to the products and for all costs related to the site transfer for all products. Pursuant to the Agreement, Elite will receive a license fee and milestone payments. The license fee will be computed as a percentage of the gross profit, as defined in the Agreement, and earned by Epic as a result of sales of the products. The license fee is payable monthly for the term of the Agreement. The first milestone payment is due on or before November 15, 2013. Subsequent milestone payments are due upon the filing of each product's supplement with the U.S. Food and Drug Administration ("FDA") and the FDA approval of site transfer for each product as specifically itemized in the agreement. The term of the License Agreement is 5 years and may be extended for an additional 5 years upon mutual agreement. "We are delighted that Elite elected to further develop our partnership by awarding this licensing agreement to Epic for these recently acquired products. This is a natural extension of our ongoing collaboration with Elite and allows Elite to leverage Epic's ability to manufacture on a large scale," said Jeenarine Narine, President and COO of Epic. Nasrat Hakim, President and CEO of Elite, stated, "Epic continues to be a valuable partner to us. Epic is able to provide significant manufacturing resources for making these large volume products and this will allow Elite to maximize our profit potential for our generic business while we devote our resources to the development of our abuse resistant products utilizing our proprietary technology."

Investor Asks a Great Question

Elite's major inside owner, Epic converted out of their Preferred. 8k released They were the major holder by far and insiders of the company. This represents almost all of Elite's preferred shares. Almost all gone except scraps... The CEO just noted they have been having discussions with major pharmaceutical companies on partnerships very recently including the CEO of one and the Chairman of another..... Listen to the R&R investors conference Why did Epic do this? A) To sell their shares? b) They didn't like having preferred shares because it made them feel superior which left a bad taste in their mouth? c) Because of substantial events upcoming which they and the company would be better served for them to be in common shares? Now before everyone starts picking A because they already sold their shares.... Epic already had plenty of shares to sell which would last them many, many quarters, can't sell these for 6 months, and is restricted in what they can sell and how often, so we KNOW selection "A" is not the correct answer. So it is B or C.. ?